NCT07028086View on ClinicalTrials.gov

VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

April 30, 2028

Conditions
Acute Myeloid LeukemiaMyeloid Sarcoma
Interventions
DRUG

VAM_GROUP

Mitoxantrone Liposome 24mg/m², IV, administered as a single dose or divided doses at the investigator's discretion based on the patient's condition; Azacitidine 75mg/m², IV drip, Day 1 to Day 7; Venetoclax 100mg on Day 1, 200mg on Day 2, and 400mg on Day 3 to Day 14.

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT07028086 - VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | Biotech Hunter | Biotech Hunter